Welcome to the UPF Digital Repository

Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.

Show simple item record

dc.contributor.author Álvarez Larrán, Alberto
dc.contributor.author Angona Figueras, Anna
dc.contributor.author Ancochea Serra, Agueda
dc.contributor.author García-Pallarols, Francesc
dc.contributor.author Fernández Rodríguez, M. Concepción
dc.contributor.author Longarón Rozalen, Raquel
dc.contributor.author Bellosillo Paricio, Beatriz
dc.contributor.author Besses Raebel, Carles
dc.date.accessioned 2016-02-25T10:53:10Z
dc.date.available 2017-01-31T03:00:05Z
dc.date.issued 2016
dc.identifier.citation Alvarez-Larrán A, Angona A, Ancochea A, García-Pallarols F, Fernández C, Longarón R. et al Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. Eur J Haematol. 2016 Jan;96(1):83-9. DOI: 10.1111/ejh.12552.
dc.identifier.issn 0902-4441
dc.identifier.uri http://hdl.handle.net/10230/25945
dc.description.abstract Masked polycythaemia vera (PV) has been proposed as a new entity with poorer outcome than overt PV. In this study, the initial clinical and laboratory characteristics, response to treatment and outcome of masked and overt PV were compared using red cell mass and haemoglobin or haematocrit levels for the distinction between both entities. Sixty-eight of 151 PV patients (45%) were classified as masked PV according to World Health Organisation diagnostic criteria, whereas 16 (11%) were classified as masked PV using the British Committee for Standards in Haematology (BCSH). In comparison with overt PV, a higher platelet count and a lower JAK2V617F allele burden at diagnosis were observed in masked PV. Patients with masked PV needed lower phlebotomies and responded faster to hydroxcarbamide than those with overt PV. Complete haematological response was more frequently achieved in masked than in overt PV (79% vs. 58%, P = 0.001). There were no significant differences in the duration of haematological response, the rate of resistance or intolerance to hydroxycarbamide and the probability of molecular response according to type of PV (masked vs. overt). Overall survival, rate of thrombosis and major bleeding, and probability of transformation was superimposable among patients with masked and overt PV.
dc.description.sponsorship This work was supported by grants from the Spanish Health Ministry ‘Fondo de Investigación Sanitaria’, PI10/01807,PI13/00557, PI13/00393, AECC Cataluña 2011, Instituto de Salud Carlos III FEDER RD12/0036/0010, SGR2014 567,the ‘Xarxa de Bancs de Tumors sponsored by Pla Director d’Oncologia de Catalunya (XBTC)’. Anna Angona is currently supported by a research grant from RETICS RD12/0036/0010.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartof European Journal of Haematology. 2016 Jan;96(1):83-9
dc.rights © 2015 Wiley -Blackwell . The definitive version is available online at: http://dx.doi.org/10.1111/ejh.12552
dc.subject.other Polycythemia Vera
dc.subject.other Tumors
dc.title Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1111/ejh.12552
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking